Chimeric Therapeutics Limited is trading 7% down today at $0.07 following several days of incremental declines and typical micro-cap biotech volatility.
- There have been no new ASX announcements, clinical trial updates, or broker notes released around June 18–19, 2026, to explain the price movement.
- The decline appears to be driven by low-liquidity trading and general risk-off sentiment rather than a specific company-specific catalyst.